Amgen Inc. (AMGN)
EMA recommends revoking marketing authorisation for Amgen's rare-disease drug
The European Medicines Agency on Friday recommended revoking the marketing authorisation for Amgen's rare autoimmune disease drug, Tavneos, citing a lack of benefits that outweigh its risks.
Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know
In the most recent trading session, Amgen (AMGN) closed at $351.93, indicating a +1.42% shift from the previous trading day.
Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?
AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw Amgen (AMGN) settling at $341.66, representing a -1.78% change from its previous close.
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent American Diabetes Association (ADA) Scientific Sessions in New Orleans.
Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?
MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.
Amgen Inc. (AMGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amgen Inc. (AMGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amgen Eyes 2026 ‘Springboard' as Growth Drugs Offset Patent Pressure
Amgen NASDAQ: AMGN executives said the company's first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
